Tag Archive for: boston

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

/in

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]

Read more

AstronauTx and STORM recognised at inaugural One Nucleus Awards

/in

Congratulations to our clients AstronauTx and STORM Therapeutics, which were recognised at the inaugural One Nucleus Awards in London in March.  AstronauTx scooped the Best Performing Primary R&D Company of the Year Award, while STORM won the One Nucleus Boston Bootcamp competition aimed at getting companies “US-ready”.  AstronauTx beat off strong competition to win the […]

Read more

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

/in

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologies Vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need Boston, Massachusetts and Geneva, Switzerland, 12th February 2024 – Alys Pharmaceuticals, Inc. […]

Read more